Please assess the completion status of the following clinical trial:

Trial Title: Study of XIAP Antisense for Advanced Cancers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* histologically proven diagnosis of advanced or metastatic cancer (including solid tumours and lymphoma)~* refractory to conventional treatment, or for which no conventional therapy exists with life expectancy of at least 12 weeks~* ECOG performance status of 0 or 1~* hematological and biochemical indices as specified within one week prior to treatment~Exclusion Criteria:~* known bleeding diathesis or concurrent treatment with anticoagulants~* primary brain tumours or brain metastases~* radiotherapy (except palliative), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas and mitomycin-C)~* all toxic manifestations of previous treatment must have resolved (excepting alopecia or certain Grade 1 toxicities)~* pregnant or lactating women~* major thoracic and/or abdominal surgery in the preceding 4 weeks~* high medical risks from non-malignant systemic disease including uncontrolled infection~* hepatitis B, C or Human Immunodeficiency Virus~* allergic history to antisense agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).